Sanjay K Patole1,2, Anthony D Keil3, Elizabeth Nathan4,5, Dorota Doherty4,5, Meera Esvaran6, Karen N Simmer1,2, Patricia Conway6. 1. a Department of Neonatal Paediatrics , King Edward Memorial Hospital for Women , Perth , Australia . 2. b Centre for Neonatal Research and Education, University of Western Australia , Perth , Australia . 3. c PathWest Laboratory Medicine Western Australia , Perth , Australia . 4. d Women and Infants Research Foundation, King Edward Memorial Hospital for Women , Perth , Australia . 5. e School of Women's and Infants' Health, University of Western Australia , Perth , Australia , and. 6. f Centre for Marine Bio-Innovation (CMB), University of New South Wales , Sydney , Australia.
Abstract
BACKGROUND: Gut development, function and colonisation are impaired in animal models of prematurity with intrauterine growth restriction (IUGR). The effect of Bifidobacterium breve (B. breve) supplementation on faecal bifidobacteria in small for gestational age (SGA: birth weight <10th centile due to IUGR) preterm infants is not known. OBJECTIVE: We compared B. breve M-16V supplementation effect on faecal bifidobacteria in preterm (<33 weeks) SGA versus non-SGA infants in the two arms of our randomised controlled trial. RESULTS: There were no baseline differences in the proportion of detectable B. breve counts between SGA versus non-SGA infants [probiotic: 7 (33%) versus 22 (42%), p = 0.603; placebo: 1 (6%) versus 1 (2%), p = 0.429]. B. breve counts did not differ between SGA and non-SGA infants in response to treatment (p = 0.589), after adjusting for baseline count (p < 0.001) and treatment allocation (p < 0.001). An interaction term between growth status and treatment showed negligible change (p = 0.938). Probiotic treated SGA infants reached full feeds earlier than SGA controls (HR 2.00, 95% CI 1.05-3.82, p = 0.035): Median (IQR): 16 (12-26) versus 19 (11-25) days, after adjustment for age at starting feeds and gestation <28 weeks. CONCLUSION: Response to B. breve M-16V supplementation was not significantly different in preterm (<33 weeks) SGA versus non-SGA infants.
RCT Entities:
BACKGROUND: Gut development, function and colonisation are impaired in animal models of prematurity with intrauterine growth restriction (IUGR). The effect of Bifidobacterium breve (B. breve) supplementation on faecal bifidobacteria in small for gestational age (SGA: birth weight <10th centile due to IUGR) preterm infants is not known. OBJECTIVE: We compared B. breve M-16V supplementation effect on faecal bifidobacteria in preterm (<33 weeks) SGA versus non-SGA infants in the two arms of our randomised controlled trial. RESULTS: There were no baseline differences in the proportion of detectable B. breve counts between SGA versus non-SGA infants [probiotic: 7 (33%) versus 22 (42%), p = 0.603; placebo: 1 (6%) versus 1 (2%), p = 0.429]. B. breve counts did not differ between SGA and non-SGA infants in response to treatment (p = 0.589), after adjusting for baseline count (p < 0.001) and treatment allocation (p < 0.001). An interaction term between growth status and treatment showed negligible change (p = 0.938). Probiotic treated SGA infants reached full feeds earlier than SGA controls (HR 2.00, 95% CI 1.05-3.82, p = 0.035): Median (IQR): 16 (12-26) versus 19 (11-25) days, after adjustment for age at starting feeds and gestation <28 weeks. CONCLUSION: Response to B. breve M-16V supplementation was not significantly different in preterm (<33 weeks) SGA versus non-SGA infants.
Authors: Nicholas D Embleton; Janet E Berrington; Jon Dorling; Andrew K Ewer; Edmund Juszczak; John A Kirby; Christopher A Lamb; Clare V Lanyon; William McGuire; Christopher S Probert; Stephen P Rushton; Mark D Shirley; Christopher J Stewart; Stephen P Cummings Journal: Front Nutr Date: 2017-05-08